前列腺癌中对大剂量雄激素治疗反应的分子决定因素。
Molecular determinants of response to high-dose androgen therapy in prostate cancer.
机构信息
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Faculty of Medicine, Benha University, Benha, Egypt.
出版信息
JCI Insight. 2019 Oct 3;4(19):129715. doi: 10.1172/jci.insight.129715.
Abstract
Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of HDAs, we applied an unbiased integrative approach using genetic screens and transcriptional profiling of PC cells with or without demonstrated phenotypic sensitivity to androgen-mediated growth repression. Through this comprehensive analysis, we identified genetic events and related signaling networks that determine the response to both HDA and androgen withdrawal. We applied these findings to develop a gene signature that may serve as an early indicator of treatment response and identify men with tumors that are amenable to HDA therapy.
摘要
雄激素（HDA）治疗前列腺癌（PC）的临床试验显示出有希望的疗效，但由于缺乏识别可能的应答者的标准而受到限制。为了阐明控制 HDAs 生长抑制作用的因素，我们应用了一种无偏的综合方法，对具有或不具有雄激素介导的生长抑制表型敏感性的 PC 细胞进行遗传筛选和转录谱分析。通过这项全面的分析，我们确定了决定对 HDA 和雄激素撤退反应的遗传事件和相关信号网络。我们将这些发现应用于开发一个基因特征，该特征可能作为治疗反应的早期指标，并识别对 HDA 治疗有反应的肿瘤的男性。
相似文献
1
Molecular determinants of response to high-dose androgen therapy in prostate cancer.前列腺癌中对大剂量雄激素治疗反应的分子决定因素。
JCI Insight. 2019 Oct 3;4(19):129715. doi: 10.1172/jci.insight.129715.
2
Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.前列腺癌细胞系LNCaP在暴露于雄激素和抗雄激素后差异表达的基因。
Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8. doi: 10.1016/j.cancergencyto.2005.09.012.
3
4
Measuring the Expression of microRNAs Regulated by Androgens.测量雄激素调控的微小RNA的表达
Methods Mol Biol. 2016;1443:151-63. doi: 10.1007/978-1-4939-3724-0_10.
5
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression.雄激素受体对核心自噬和溶酶体基因的转录调控促进前列腺癌进展。
Autophagy. 2017 Mar 4;13(3):506-521. doi: 10.1080/15548627.2016.1268300. Epub 2016 Dec 15.
6
Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.雄激素通过激活前列腺癌细胞中的视网膜母细胞瘤（RB）蛋白来抑制Bcl-2表达。
Oncogene. 2004 Mar 18;23(12):2161-76. doi: 10.1038/sj.onc.1207326.
7
TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.TRIM68调节前列腺癌细胞中雄激素受体的配体依赖性转录。
Cancer Res. 2008 May 1;68(9):3486-94. doi: 10.1158/0008-5472.CAN-07-6059.
8
GREB1 is a novel androgen-regulated gene required for prostate cancer growth.GREB1是一种前列腺癌生长所需的新型雄激素调节基因。
Prostate. 2006 Jun 1;66(8):886-94. doi: 10.1002/pros.20403.
9
Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.威尔姆斯肿瘤抑制基因WT1对雄激素信号通路的转录调控。
Anticancer Res. 2001 Jan-Feb;21(1A):1-10.
10
Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: a new suppressor candidate on chromosome 13, in the BRCA2-Rb1 locus.雄激素诱导前列腺癌细胞增殖抑制过程中的早期基因表达：13号染色体上BRCA2-Rb1基因座的一个新的抑制候选基因。
J Steroid Biochem Mol Biol. 1999 Jan;68(1-2):41-50. doi: 10.1016/s0960-0760(98)00165-4.
引用本文的文献
1
RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.RNA测序揭示内分泌干扰化学物质与侵袭性前列腺癌中的枢纽基因和转录因子的关联。
Int J Mol Sci. 2025 Jun 6;26(12):5463. doi: 10.3390/ijms26125463.
2
Multi-omics analysis constructs a novel neuroendocrine prostate cancer classifier and classification system.多组学分析构建了一种新型的神经内分泌前列腺癌分类器和分类系统。
Sci Rep. 2025 Apr 22;15(1):13901. doi: 10.1038/s41598-025-96683-3.
3
Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells.在具有Rb功能正常和Rb功能缺陷细胞混合的去势抵抗性前列腺癌肿瘤中，对高剂量睾酮的异质性反应。
Mol Cancer Ther. 2025 May 2;24(5):772-783. doi: 10.1158/1535-7163.MCT-24-0716.
4
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.雄激素受体单体和二聚体调节前列腺癌细胞中相反的生物学过程。
Nat Commun. 2024 Sep 3;15(1):7675. doi: 10.1038/s41467-024-52032-y.
5
The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.前列腺癌细胞释放的外泌体的蛋白质组成受到雄激素受体拮抗剂和激动剂的明显调节，以刺激靶细胞的生长。
Cell Commun Signal. 2024 Apr 8;22(1):219. doi: 10.1186/s12964-024-01584-z.
6
A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.一个双等位基因的多核苷酸长度多态性解释了 5p15.33 前列腺癌风险位点的功能因果关系。
Nat Commun. 2023 Aug 23;14(1):5118. doi: 10.1038/s41467-023-40616-z.
7
Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire.双相雄激素疗法：当过量燃料扑灭火焰时。
Biomedicines. 2023 Jul 24;11(7):2084. doi: 10.3390/biomedicines11072084.
8
Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.卡罗来纳乳腺癌研究中雄激素受体低、雌激素受体阴性乳腺癌的分子特征。
Breast Cancer Res Treat. 2023 Sep;201(2):171-181. doi: 10.1007/s10549-023-07014-x. Epub 2023 Jul 12.
9
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer.晚期前列腺癌雄激素产生、摄取和转化（APUC）途径中的调控基因。
Endocr Oncol. 2022 Jun 7;2(1):R51-R64. doi: 10.1530/EO-22-0058. eCollection 2022 Jan.
10
Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.理解人类衰老以及与年龄相关疾病中的基本细胞信号传导联系：中年血管减少性缺氧假说。
Front Aging. 2023 Jun 13;4:1196648. doi: 10.3389/fragi.2023.1196648. eCollection 2023.
本文引用的文献
1
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.恩扎卢胺耐药性前列腺癌对超生理剂量睾酮的持久反应与患者来源的异种移植物中多方面的生长抑制和受损的 DNA 损伤反应转录组程序有关。
Eur Urol. 2020 Feb;77(2):144-155. doi: 10.1016/j.eururo.2019.05.042. Epub 2019 Jun 19.
2
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.雄激素受体剪接变异体-7 的表达随着前列腺癌的去势抵抗而出现。
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.
3
Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway.蛋白组学分析表明，炭吸附处理胎牛血清中胰岛素样生长因子信号通路发生改变。
J Proteome Res. 2018 Sep 7;17(9):2963-2977. doi: 10.1021/acs.jproteome.8b00135. Epub 2018 Aug 3.
4
SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.SREBF1 活性受前列腺癌中 AR/mTOR 核轴的调节。
Mol Cancer Res. 2018 Sep;16(9):1396-1405. doi: 10.1158/1541-7786.MCR-17-0410. Epub 2018 May 21.
5
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.转移性去势抵抗性前列腺癌患者在恩扎卢胺治疗进展后应用双氢睾酮治疗：一项开放标签、多队列 2 期临床研究。
Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.
6
Differential impact of RB status on E2F1 reprogramming in human cancer.RB 状态对人类癌症中 E2F1 重编程的差异影响。
J Clin Invest. 2018 Jan 2;128(1):341-358. doi: 10.1172/JCI93566. Epub 2017 Dec 4.
7
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.雄激素受体信号通路非依赖性前列腺癌通过成纤维细胞生长因子信号得以维持。
Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.
8
Integrative Clinical Genomics of Advanced Prostate Cancer.晚期前列腺癌的综合临床基因组学
Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053.
9
Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.短暂暴露于雄激素会在分散的前列腺癌细胞中诱导出一种显著的自我维持静止状态。
Cell Cycle. 2017 May 3;16(9):879-893. doi: 10.1080/15384101.2017.1310345. Epub 2017 Apr 20.
10
Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells.雄激素通过成纤维细胞生长因子受体底物2抑制前列腺癌细胞中蛋白激酶D1的表达。
Oncotarget. 2017 Feb 21;8(8):12800-12811. doi: 10.18632/oncotarget.14536.
Zotero 插件